This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Onoda, J. M. Articles by Honn, K. V. Search for Related Content PubMed PubMed Citation Articles by Onoda, J. M. Articles by Honn, K. V.

In Vivo Characterization of Combination Antitumor Chemotherapy with Calcium Channel Blockers and cis-Diamminedichloroplatinum(II)¹

Departments of Radiation Oncology [J. M. O., K. K. N., J. D. T., K. V. H.], Biological Sciences [J. D. T.], and Chemistry [K. V. H.], Wayne State University, Detroit, Michigan 48202; and the Gershenson Radiation Oncology Center [J. M. O., K. K. N., J. D. T., K. V. H.], Harper/Grace Hospitals, Detroit, Michigan 48201

We have examined nifedipine, a dihydropyridine class calcium channel blocker, for ability to overcome cis-diamminedichloroplatinum(II) (cisplatin) resistance in a murine tumor line variant, B16a-Pt, which we developed for resistance to cisplatin. Nifedipine significantly enhanced the antitumor actions of cisplatin against primary subcutaneous B16a-Pt tumors and their spontaneous pulmonary metastases. We have characterized, in vivo, the pharmacokinetics and dose-response interactions between nifedipine and cisplatin. We now report our studies designed to compare, in vivo, the efficacy of nifedipine and other calcium active compounds including: (a) structurally similar calcium channel blockers (nimodipine, nicardipine) from the dihydropyridine class, (b) structurally different calcium channel blockers from the benzothiazepine (diltiazem) and the phenylalkylamine (verapamil) classes, and (c) calmodulin antagonists (trifluoperazine and calmidazolium) for ability to enhance the antitumor action of cisplatin. Nifedipine was included as the standard or reference compound. In these studies verapamil and diltiazem failed to enhance the antitumor actions of cisplatin as did both calmodulin antagonists. Our findings suggest that nifedipine has a greater degree of specificity for B16a-Pt cells than structurally different calcium channel blockers from other chemical classes (i.e., diltiazem and verapamil), or the two calmodulin antagonists (i.e., trifluoperazine and calmidazolium). We concluded that nifedipine interacts with specific target site(s) which are not accessible by verapamil, by diltiazem, or by the calmodulin antagonists. Surprisingly, the two dihydropyridine class calcium channel blockers, nimodipine and nicardipine, also failed to enhance cisplatin's antitumor actions despite the fact that their specificity and kinetics for binding to the dihydropyridine receptor component of the calcium channel favors them (nimodipine and nicardipine) over nifedipine. Therefore, we postulate that the synergism between cisplatin and nifedipine is independent of the latter's effect on the voltage sensitive, slow inward calcium channel.

We suggest that cisplatin cytotoxicity is enhanced by nifedipine's interaction with an as yet unidentified specific "target site," as opposed to nonspecific interactions with the tumor cell plasma membrane or specific interactions with calmodulin or the P-glycoprotein (which is responsible for pleiotropic resistance).

¹ This investigation was partially supported by a grant from the Meyer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit, Detroit, MI 48201 [85-SC11: J. M. O.], and a grant from Harper Hospital [J. M. O., K. V. H.], Detroit, Michigan, 48201.

² To whom requests for reprints should be addressed, at Department of Radiation Oncology, 431 Chemistry Building, Wayne State University, Detroit, Michigan 48202.

Received 9/20/88. Revised 1/30/89. Accepted 3/ 3/89.